Based on public messages from Alan and also when I spoke to him 1:1 at a conference in Sydney in November Alan has always said that they will not give a patient an extra dose just because the trial design says 4 doses if the patient is showing nearly full response in 1, 2 or 3 doses. Similarly they will not give patients a higher dose if they are responding at a lower dose level. This is how clinicians will treat their patients in the real world. So I guess we just have to wait for announcements to know how they went with the trials and which would be patient response based instead of a blanket regimen.
This is IMHO only and I could be wrong. DYOR.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-16
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.48 |
Change
0.085(3.56%) |
Mkt cap ! $794.0M | |||
| Open | High | Low | Value | Volume |
| $2.39 | $2.53 | $2.37 | $3.115M | 1.263M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 33 | 20576 | $2.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.48 | 36990 | 25 |
View Market Depth
| Last trade - 13.47pm 27/06/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |